Philip Newsome
Philip Newsome is the director of the Roger Williams Institute of Liver Studies at King's College London and a prominent researcher in hepatology. He is known for his work on liver diseases, particularly non-alcoholic fatty liver disease (NAFLD), and has contributed significantly to understanding the effects of treatments like semaglutide on advanced liver conditions. Recently, he was involved in a groundbreaking study published in The New England Journal of Medicine, which highlighted the potential of semaglutide to not only reduce liver inflammation but also to reverse fibrosis in patients with advanced metabolic dysfunction-related liver disease.
Not in the pool (under ¢1).
Recent news mentions
Prof Philip Newsome of King’s College London presented findings on the effects of semaglutide in patients with fatty liver disease.
How weight-loss wonder drugs are redefining the way our bodies work | Obesity
United Kingdom· 2025-05-17
Professor Philip Newsome from King's College London led a large trial that included 1,195 MASH patients across 253 clinical sites in 37 countries.
זריקת הרזיה וויגובי יעילה בטיפול במחלת כבד שומני
Israel· 2025-05-03
Professor Philip Newsome from King's College London led the trial showing the benefits of semaglutide for patients with metabolic-associated fatty liver disease.
دواء شهير للسكري والسمنة يعالج مرض الكبد الدهني بفعالية
Saudi Arabia· 2025-05-03
Professor Philip Newsome, director of the Roger Williams Institute of Liver Studies at King's College London, leads the trial and discusses the effectiveness of semaglutide.
Severe liver disease reversed with semaglutide injections, study reveals
United States· 2025-05-03
Philip Newsome is the director of the Roger Williams Institute of Hepatic Studies at King's College and the author of the study.
El universo Ozempic se expande: estos fármacos también sirven para tratar el hígado graso | Salud y bienestar
Spain· 2025-04-30
